Form 4: Avalo Therapeutics Insider Trades Common Stock

Avalo Therapeutics reports insider transactions involving common stock and stock options, executed under a Rule 10b5-1 trading plan.

Summary

• Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc., reported transactions on May 15, 2026.
• Doyle acquired 3,000 shares of common stock at a price of $12.65 per share.
• Concurrently, Doyle disposed of 3,000 shares of common stock at a price of $18.76 per share.
• These transactions were executed as part of a Rule 10b5-1 trading plan adopted on November 13, 2025.
• Following these transactions, Doyle beneficially owns 3,622 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves insider transactions, the execution under a pre-defined Rule 10b5-1 plan mitigates negative sentiment, indicating a planned rather than reactive sale.

Positives

• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a structured and pre-determined approach to insider trading.
• The acquisition of shares at a lower price ($12.65) and disposal at a higher price ($18.76) suggests a profitable execution within the plan.

Negatives

• A net of 3,000 shares were disposed of, reducing the insider's direct holdings.
• The disposal price of $18.76 is significantly higher than the acquisition price of $12.65, indicating a sale at a profit.

Risks

• The disposal of shares by a key executive could be interpreted negatively by the market, potentially signaling a lack of confidence in near-term stock performance, despite being part of a pre-planned strategy.
• The specific details of the Rule 10b5-1 plan, such as its duration and the rationale behind the specific transaction amounts and prices, are not fully disclosed in this filing.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
• The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan is a common strategy for executives to diversify holdings or manage personal finances while mitigating concerns about insider trading.

Stakeholder Impact

• Shareholders: The disposal of shares by an executive, even under a plan, may lead to short-term market perception shifts. However, the structured nature of the trade under Rule 10b5-1 aims to reduce this impact.
• Employees: The vesting schedule for stock options provides an incentive for continued employment and service.
• Management: The transactions reflect the executive's personal financial planning and adherence to compliance protocols.

Next Steps

• Continued vesting of stock options over the next three years, subject to continued service.
• Potential future transactions under the existing Rule 10b5-1 plan or new plans.

Key Dates

Keywords

Form 4, Insider Trading, Avalo Therapeutics, AVTX, Rule 10b5-1, Stock Options, Common Stock, Beneficial Ownership, SEC Filing, Executive Transactions